Feline panleukopenia (FPL), caused by the feline panleukopenia virus (FPLV), is a severe and highly contagious viral disease with high morbidity and mortality. Vaccination remains the gold standard for preventing and controlling this debilitating condition. The viral protein VP2 serves as the major immunogen of FPLV and represents the key target antigen in the development of a novel FPLV vaccine. Virus-like particle (VLP)-based vaccines have emerged as next-generation vaccine candidates due to their high immunogenicity and safe profile. In this study, a baculovirus expression vector system (BEVS) was employed to generate FPLV-VLPs through recombinant expression of the VP2 protein of a Chinese epidemic strain (Ala91Ser, Ile101Thr) of FPLV. The resulting FPLV-VLPs demonstrated markedly enhanced antigenicity and hemagglutination activity, achieving a hemagglutination titer of up to 1:216. Following vaccination, immunized cats developed high titers of anti-FPLV hemagglutination inhibition (HI) antibodies (1:216) and exhibited 100% protection against challenge with a virulent epidemic FPLV variant (Ala91Ser, Ile101Thr). These findings demonstrate that FPLV-VLPs hold strong potential as candidates for a novel subunit vaccine against FPLV infection.
Feline panleukopenia (FPL), caused by feline panleukopenia virus (FPLV), is a severe and highly contagious viral disease with high morbidity and mortality. Vaccination remains the gold standard for prevention and control this debilitating condition. The viral protein (VP2) serves as the major immunogen of FPLV and represents the key target antigen in the development of novel FPLV Vaccine. Virus-like particles(VLPs)-based vaccines have been emerged as the next-generation vaccine candidates due to their high immunogenicity and safe profile. In this study, a baculovirus expression vector system (BEVS) was employed to generate FPLV-VLPs through recombinant expression of the VP2 protein of a Chinese epidemic strain (Ala91Ser, Ile101Thr) of FPLV. The resulting FPLV-VLPs demonstrated markedly enhanced antigenicity and hemagglutination activity, achieving a hemagglutination titer of up to 1:216. Following vaccination, immunized cats developed high titers of anti-FPLV hemagglutination inhibition (HI) antibodies (1:216) and exhibited 100% protection against challenge with a virulent epidemic FPLV variant (Ala91Ser, Ile101Thr). These findings demonstrate that FPLV-VLPs hold strong potential as candidates for a novel subunit vaccine against FPLV infection.
Feline herpesvirus type-1 (FHV-1), a double-stranded DNA virus, which is a highly infectious upper respiratory tract infection of felids, particularly in kittens. Droplet digital PCR (ddPCR) provides an absolute quantification method with high sensitivity and accuracy. This study aimed to develop a highly sensitive and accurate ddPCR assay for the detection of FHV-1. We designed primers and a probe targeting the FHV-1 glycoprotein D (gD) gene and evaluated the assay’s limit of detection (LOD), sensitivity, repeatability, and specificity in comparison to quantitative real-time PCR (qPCR). The developed ddPCR assay demonstrated a strong linear dynamic range (R2 ≥ 0.99) and an exceptionally low LOD of 0.18 copies/μL, which was significantly more sensitive than the method qPCR (LOD ~10 copies/μL). Additionally, the assay exhibited high specificity with no cross-reactivity against other common feline pathogens (feline calicivirus, FCV; feline panleukopenia virus, FPV; feline infectious peritonitis virus, FIPV; Bordetella bronchiseptica and Chlamydia felis) and displayed outstanding repeatability (inter-run CV < 1.35). When applied to 118 clinical samples, the ddPCR assay achieved a significantly higher positive detection rate (27.4%) compared to qPCR (14.8%). In conclusion, we have successfully established a reliable ddPCR assay for the absolute quantification of FHV-1, providing a superior tool for laboratory diagnosis and research.
Pigeon circovirus (PiCV) is an important pathogen that infects pigeons, which can induce multiple disorders such as immunosuppression and respiratory symptoms, posing a serious threat to the pigeon industry. In this study, we combined the RAA and CRISPR/Cas12a assay to establish a highly sensitive and accurate detection method for PiCV. This detection method amplifies the target nucleic acids through RAA; and the resultant dsDNA is specifically recognized by crRNA, the trans-cleavage activity of Cas12a is activated, which further cleaves the fluorescent reporter group to generate a fluorescent signal that can be visually observed under blue light. The method established in this study exhibited high sensitivity, with a minimum detection limit of 6.08 copies/µL. It showed no cross-reactivity with non-PiCV samples, demonstrating high specificity. When 40 clinical samples were tested by this method and quantitative polymerase chain reaction (qPCR) respectively, the coincidence rate was 92.5%, and the method developed herein achieved a higher positive detection rate. In conclusion, we successfully developed a rapid, on-site operable, one-step visual detection method for PiCV, which holds promising application prospects.
Feline panleukopenia virus (FPLV) is a significant causative agent of disease in both domestic cats and wild carnivores that poses a considerable threat to their health. Despite its clinical importance, the mechanisms underlying FPLV–host interactions remain poorly understood. In this study, we conducted a systematic analysis of transcriptomic changes in feline kidney cells (F81) infected with a Chinese FPLV strain using RNA-seq. The down-regulated differentially expressed genes (DEGs) were majorly enriched in the regulation of the cell cycle, cell growth, or cell senescence, while the up-regulated DEGs were found to be significantly associated with cellular pathways involved in cell cycle regulation, extrinsic apoptotic signaling, and key host immune responses, including Toll-like receptor, JAK-STAT, IL-17, and TNF signaling pathways. By validating the RNA-seq data with RT-qPCR (real-time quantitative PCR) results, we identified potentially important immune-associated genes involved in the host immune response to feline panleukopenia virus, including IGSF6, IFI44L, IFI6, IFITM10, IL1R1, and JAK3. Overall, our results provide valuable insights into the mechanisms underlying feline panleukopenia virus and its interactions with its host, laying the foundation for future research on this significant virus and its impact on feline health.
Feline panleukopenia virus (FPLV) is the primary causative agent of a highly contagious and often fatal disease affecting domestic cats and other felids. The increasing isolation of species-specific FPLV variants from multiple host species has garnered considerable attention, highlighting the need to investigate their genetic diversity. In this study, three FPLV isolates were obtained and phylogenetically classified into two distinct FPLV-China groups within separate clusters. Compared to the prototype FPLV (M38246.1), these isolates exhibited seven amino acid substitutions in the NS1 (n = 6) and VP2 (n = 1) proteins. Further analysis of 157 NS1 sequences and 947 VP2 sequences retrieved from the NCBI database revealed 113 and 479 synonymous substitutions and 71 and 279 non-synonymous substitutions, respectively. Notably, the majority of these substitutions occurred as single events (57% in NS1, 40/71; 55% in VP2, 153/279) or were present in no more than five FPLV sequences (23% in NS1, 16/71; 32% in VP2, 89/279). However, three non-synonymous substitutions in the NS1 protein (Ile443Val, His595Gln, and Val596Leu) were detected in more than half of the 157 sequences analyzed. In the VP2 protein, six non-synonymous substitutions (Ala91Ser, Thr101Ile, Val232Ile, Lys93Asn, Asp323Asn, and Val562Leu) were each found in 20 to 40 FPLV sequences. Furthermore, ten sites in the NS protein and 224 sites in the VP2 protein exhibited both synonymous and non-synonymous substitutions simultaneously. Additionally, 75 sites in VP2 harbored multiple non-synonymous substitutions. These findings provide valuable insights for future research on the genetic determinants and vaccine development of FPLV.